A
Alcista
Alcista · 25%GILD
$120.97
Precio del escenario
$147.920
-2.470 (-1.67%)Al cierre
Loading chart…
- Máximo
- 151.160
- Apertura
- 151.160
- Precio medio ponderado por volumen
- 148.78
- Volumen
- 5.56M
- Capitalización
- 85.75B
- Mínimo
- 147.260
- Importe
- 826.95M
- EV/EBITDA, TTM
- 15.19
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.
Análisis de IA of Gilead Sciences, Inc (GILD)
ComprarGilead Sciences Inc is a good buy right now due to its current price of $151.17, which is below several analyst price targets, including $170 from JPMorgan and $175 from HSBC. The stock has shown strong momentum with a 5-day change of +4.44% and a year-to-date change of +24.32%. However, the main risk is the recent negative net income reported for Q2 2026, which was -10.496 billion USD, indicating potential volatility ahead.
Recomendaciones de analistas (28)
-6.79% Potencial de caída
Mantener
13 Comprar
15 Mantener
0 Vender
Actual: 147.92
Mínimo
105.00
Promedio
137.88
Máximo
154.00
BofA
Comprar
$168
2026-10-12
BofA
2026-10-12
Precio objetivo
$168
Comprar
RBC Capital
Sector Perform
$126
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$126
Sector Perform
Morgan Stanley
Sobreponderar
$163
2026-10-07
Morgan Stanley
2026-10-07
Precio objetivo
$163
Sobreponderar
Truist
Comprar
$158
2026-10-07
Truist
2026-10-07
Precio objetivo
$158
Comprar
JPMorgan
Sobreponderar
$170
2026-10-07
JPMorgan
2026-10-07
Precio objetivo
$170
Sobreponderar
Métricas de valoración
El PER previsto actual de Gilead Sciences, Inc (GILD) es 15.55, frente a su media de 5 años de 12.42.
Escenarios de precio de Alphio AI para GILD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con GILD en cartera
Cronología de eventos
Noticias
9.510-10CNBCBank of America Sees Strong Buying Opportunities Ahead of Q3 Earnings
7.510-09CNBCEmily's Entourage Drives Hope for Cystic Fibrosis Patients
4.510-05stocktwitsMarket Impact Analysis of Midterm Elections
7.510-05NewsfilterAstraZeneca Invests in Next-Gen Cancer Drug Development
7.510-05CNBCAstraZeneca Invests in New Drug Development Center
Preguntas frecuentes sobre GILD, respondidas por Alphio AI
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Gilead Sciences Inc is a good buy right now due to its current price of $151.17, which is below several analyst price targets, including $170 from JPMorgan and $175 from HSBC. The stock has shown strong momentum with a 5-day change of +4.44% and a year-to-date change of +24.32%. However, the main risk is the recent negative net income reported for Q2 2026, which was -10.496 billion USD, indicating potential volatility ahead.
28 analysts cover GILD: 13 rate it Buy, 15 Hold and 0 Sell. The average price target is 137.88.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.